Derrell D Porter, M D , Elected to Board of Directors of Passage Bio
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
In 2020, Passage Bio , a genetic medicines company focused on rare disorders of the central nervous system, boasted a workforce of 20. That number has jumped to 100, with the aim of reaching 150 this year, according to CEO Bruce Goldsmith . The Center City-based company’s quick expansion signals the uptick in employment opportunities and economic growth among the three dozen cell therapy, gene therapy , and gene editing companies located across the Philadelphia region. Last year, the Philadelphia region’s entire life sciences hub ranked sixth in the United States, according to the JLL 2020 U.S. Life Sciences Real Estate Outlook , which tracks trends in the field, based on “new peaks in capital venture investment and life sciences employment.”
Message :
Required fields
Passage Bio collaborator University of Pennsylvania’s Gene Therapy Program to present poster regarding development of a novel mouse model for evaluating efficacy of adeno-associated virus gene therapy for metachromatic leukodystrophy (MLD)
Passage Bio gene therapy candidate, PBML04, showed preliminary signs of efficacy in novel mouse model of MLD
PHILADELPHIA, May 11, 2021 (GLOBE NEWSWIRE) Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for rare monogenic central nervous system (CNS) disorders, announced today the presentation by its collaborator University of Pennsylvania’s Gene Therapy Program (GTP) of a digital poster at the 24th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT). Gourav Roy Choudhury, Ph.D., a senior research investigator at GTP, will report on the development and utility of a novel Arylsulfatase A-deficient mouse model in reprodu
Published: May 03, 2021 By Brandon May
During a talk last month, the Chief Executive Officer (CEO) of biotech company BioVia said she was waiting for results from a six-person study performed in Mexico that saw patients with dementia receive a controversial gene therapy injection not yet authorized by the U.S. Food and Drug Administration (FDA). If actually administered to these patients, this could represent the first recorded attempt to manage dementia that uses an injectable gene therapy technique.
Elizabeth Parrish, CEO of the Seattle-based startup BioVia, suggests the current drug safety regulatory system set up in the U.S. is a substantial barrier to potentially lifesaving and life-lengthening therapies. Her biotech includes an advisory board committee that boasts George Church, a Harvard geneticist.
vimarsana © 2020. All Rights Reserved.